Christopher Y Park

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Cancer stem cell-directed therapies: recent data from the laboratory and clinic
    Christopher Y Park
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, California, USA
    Mol Ther 17:219-30. 2009
  2. pmc Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Palo Alto, California, USA
    Cancer Res 71:1374-84. 2011
  3. pmc Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
    Wendy W Pang
    Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research and Medicine, and Department of Pathology, Stanford University, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 110:3011-6. 2013
  4. doi request reprint Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305, USA
    Sci Transl Med 2:63ra94. 2010
  5. doi request reprint In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood
    Christopher Y Park
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, California 94304, USA
    Nat Protoc 3:1932-40. 2008
  6. pmc Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford University, Palo Alto, CA 94304, USA
    Cell 142:699-713. 2010
  7. pmc Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome
    Kelly A McGowan
    Departments of Genetics, Stanford University, Stanford, CA, USA
    Blood 118:3622-33. 2011
  8. pmc CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
    Siddhartha Jaiswal
    Ludwig Center at Stanford, Stanford Cancer Center, Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell 138:271-85. 2009
  9. pmc Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell Stem Cell 1:635-45. 2007
  10. doi request reprint CNS T-cell lymphoma: an under-recognized entity?
    Mohanpal Singh Dulai
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Edwards Room R 241, Stanford, CA 94305, USA
    Acta Neuropathol 115:345-56. 2008

Collaborators

Detail Information

Publications10

  1. pmc Cancer stem cell-directed therapies: recent data from the laboratory and clinic
    Christopher Y Park
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, California, USA
    Mol Ther 17:219-30. 2009
    ..Herein, we highlight recent studies that demonstrate the utility of CSC-directed therapies and discuss the implications of the CSC hypothesis to experimental design and therapeutic strategies...
  2. pmc Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Palo Alto, California, USA
    Cancer Res 71:1374-84. 2011
    ..These data provide preclinical support for the development of an anti-CD47 antibody therapy for treatment of human ALL...
  3. pmc Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
    Wendy W Pang
    Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research and Medicine, and Department of Pathology, Stanford University, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 110:3011-6. 2013
    ....
  4. doi request reprint Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford, CA 94305, USA
    Sci Transl Med 2:63ra94. 2010
    ....
  5. doi request reprint In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood
    Christopher Y Park
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, California 94304, USA
    Nat Protoc 3:1932-40. 2008
    ..Short-term and long-term engraftment is assessed 4-6 weeks and 10-12 weeks post-transplantation, respectively, with preparation and analysis time requiring 4-8 h at each time point...
  6. pmc Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
    Mark P Chao
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, and Ludwig Center at Stanford, Stanford University, Palo Alto, CA 94304, USA
    Cell 142:699-713. 2010
    ..These antibodies synergized through a mechanism combining Fc receptor (FcR)-dependent and FcR-independent stimulation of phagocytosis that might be applicable to many other cancers...
  7. pmc Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome
    Kelly A McGowan
    Departments of Genetics, Stanford University, Stanford, CA, USA
    Blood 118:3622-33. 2011
    ....
  8. pmc CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
    Siddhartha Jaiswal
    Ludwig Center at Stanford, Stanford Cancer Center, Department of Pathology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cell 138:271-85. 2009
    ..We conclude that CD47 upregulation is an important mechanism that provides protection to normal HSCs during inflammation-mediated mobilization, and that leukemic progenitors co-opt this ability in order to evade macrophage killing...
  9. pmc Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood
    Ravindra Majeti
    Department of Internal Medicine, Division of Hematology, Stanford University, Palo Alto, CA 94304, USA
    Cell Stem Cell 1:635-45. 2007
    ..Furthermore, we report the first prospective isolation of a population of candidate human multipotent progenitors, Lin-CD34+CD38-CD90-CD45RA- cord blood...
  10. doi request reprint CNS T-cell lymphoma: an under-recognized entity?
    Mohanpal Singh Dulai
    Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Edwards Room R 241, Stanford, CA 94305, USA
    Acta Neuropathol 115:345-56. 2008
    ....

Research Grants2

  1. Functional role of microRNA in acute myeloid leukemia stem cells and their normal
    CHRISTOPHER PARK; Fiscal Year: 2007
    ..Given the strength of Stanford's clinical divisions (adult and pediatric hematology/oncology, bone marrow transplant, hematopathology), there is significant tissue access as well as opportunities to work with clinical colleagues. ..